Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
Studies from Mie University, Medical Department further understanding of vaccines
May 6th, 2008
According to recent research published in the journal Cancer Science, "The CHP-HER2 vaccine, comprising truncated 146HER2 protein complexed with nanogels of cholesteryl pullulan (CHP), is a novel protein antigen vaccine that elicits 146HER2-specific CD8(+) and CD4(+) T-cell immune responses in patients with HER2-expressing tumors. We analyzed the humoral responses in patients vaccinated with CHP-HER2 and those with CHP-HER2 plus granulocyte-macrophage colony-stimulating factor (GM-CSF)." "The vaccine was injected subcutaneously at a dose of 300 mu g protein. Nine patients received the vaccine alone over the first four injections, followed by CHP-HER2 with GM-CSF...
Source: Cancer Weekly (2008-05-06)
|
